A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
2026 milestones and potential regulatory steps across Becker muscular dystrophy and hypertrophic cardiomyopathy programs. See our latest analysis for Edgewise Therapeutics. The J.P. Morgan update comes after a strong 90 day share price return of 59.73%, alongside a more mixed picture that includes a 1 year total shareholder return decline of 9.34% and a 3 year total shareholder return of 120.21%. If the Becker and cardiomyopathy data have caught your attention, this could be a good moment to broaden your watchlist with other healthcare stocks that are moving on clinical or regulatory milestones. With the shares up 59.73% over 90 days, but still carrying a value score of 1 and a last close of $24.95 versus a US$38.17 analyst target, you have to ask: is there still a buying opportunity here, or has the market already priced in the pipeline milestones? Edgewise Therapeutics trades on a P/B of 4.7x, and with a last close of $24.95, the key question is whether that premium stacks
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026PR Newswire
- Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026PR Newswire
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR Newswire
- This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits [Yahoo! Finance]Yahoo! Finance
- Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst [Seeking Alpha]Seeking Alpha
EWTX
Earnings
- 11/6/25 - Beat
EWTX
Sec Filings
- 1/15/26 - Form 144
- 1/5/26 - Form 4
- 12/29/25 - Form 144
- EWTX's page on the SEC website